Oraya Therapeutics demonstrates its IRay, a low-voltage, stereotactic, radiosurgical system’s ability to reduce or halt effects of wet age-related macular degeneration in treated patients, plus “signifcantly” lower the frequency of anti-VEGF injections for patients.